Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors

Enoch Kariuki, Pharm.D., a seasoned life sciences executive, has been appointed to the Board of Directors of Endeavor BioMedicines, a clinical-stage company focused on developing therapies for fibrotic disease and oncology. With his extensive strategic, operational, and financial experience, Dr. Kariuki is expected to bring valuable insights to advance the company's pipeline of therapies for fibrosis and cancer.

Dr. Kariuki's impressive background includes over fifteen years of experience in healthcare strategy, life sciences investment banking, venture capital, and business development. Prior to joining Endeavor BioMedicines, he held executive positions in various companies, such as Lengo Therapeutics, VelosBio, and Synthorx, where he played key roles in financial management, corporate development, and investor relations. He also served as a vice president at H.I.G. Capital, a prominent private equity firm.

Endeavor BioMedicines' CEO, John Hood, Ph.D., expressed his excitement about Dr. Kariuki joining the board, stating that his executive leadership, corporate development expertise, and operational skills would prove invaluable as the company continues to expand its clinical programs. The company is focused on the development of ENV-101 for the treatment of fibrotic lung diseases and ENV-501 for HER3 expressing tumors.

Dr. Kariuki also expressed his enthusiasm for joining Endeavor BioMedicines, praising the company's innovative pipeline of therapeutic options for fibrosis and cancer. He highlighted the talented management team and their ability to execute the development strategy. Dr. Kariuki looks forward to collaborating with the other board members and management to bring new treatment options to patients in need.

About Endeavor BioMedicines

Endeavor BioMedicines, Inc., is a clinical-stage company specializing in the development of novel therapies for fibrosis and oncology. The company combines cutting-edge therapeutics with a comprehensive understanding of terminal diseases to create medicines with the potential to reverse severe health conditions. Their lead program, ENV-101, is currently in Phase 2 studies as a Hedgehog signaling inhibitor for idiopathic pulmonary fibrosis (IPF). Additionally, they are preparing for the clinical development of a HER3-targeted antibody drug conjugate (ADC) for the treatment of multiple solid tumors in 2024.

Endeavor BioMedicines boasts an innovative and dedicated team focused on developing therapeutics that improve patients' quality of life and longevity. For more information about the company, please visit their official website or connect with them on LinkedIn and Twitter.

Conclusion

With the appointment of Enoch Kariuki, Pharm.D., to the Board of Directors, Endeavor BioMedicines has gained a valuable asset with extensive experience in the life sciences industry. Dr. Kariuki's expertise in strategic decision-making, financial management, and operational execution is expected to play a significant role in advancing the company's pipeline of therapies for fibrotic diseases and oncology.

Endeavor BioMedicines is focused on developing innovative treatment options for fibrosis and cancer, aiming to make a positive impact on patients' lives. With their lead program, ENV-101, and a HER3-targeted antibody drug conjugate in the pipeline, the company is well-positioned for success in bringing novel therapies to market.

As the company continues to grow, the addition of Dr. Kariuki to the board underscores their commitment to assembling a highly skilled team capable of driving effective clinical programs and corporate development strategies. Endeavor BioMedicines' dedication to improving patient outcomes, coupled with their talented management team, makes them an exciting and promising company in the field of fibrosis and oncology therapeutics.